Abstract
In the treatment of inflammatory bowel disease the main anti-inflammatory component of sulphasalazine is 5-ASA. Based on the same azo-splitting principle in the colon as sulphasalazine, the new drug olsalazine was developed. Olsalazine consists of two 5-ASA molecules joined by an azo bridge. Pharmacokinetic studies have shown that on oral administration there is little systemic absorption of olsalazine. Almost the whole dose passes into the colon, where the olsalazine is completely split into 5-ASA and subsequently excreted in faeces and urine. It can be concluded that from all toxicological and pharmacological aspects, olsalazine is a safe drug. Olsalazine will present the colonic mucosa with twice the amount of 5-ASA/unit compared with sulphasalazine (the present drug of choice) without concomitant delivery of sulphapyridine, which is believed to carry most of the drug's side-effects. Thus, olsalazine seems to be a suitable drug for long-term treatment of ulcerative colitis in man.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
